About Bioness

Bioness is the leading provider of implantable and external neuromodulation systems, robotic systems and software therapy programs that provide functional and therapeutic benefits for individuals affected by pain, orthopedic injuries, and other disorders of the central nervous system. 

 

With the support of entrepreneur and philanthropist Alfred E. Mann, Bioness was formed in 2004 to help patients with neurological impairments regain their independence. Since then the company has launched many products to worldwide markets.

Bioness remains part of the Alfred Mann Foundation company portfolio.

Al Mann Bioness Founder

Alfred Mann

Bioness was founded by Alfred E. Mann, a physicist, investor, entrepreneur, and philanthropist. During his career, Mr. Mann founded and largely funded 17 companies, bringing many scientific breakthroughs to the medical community, including:

  • Cochlear implants from Advanced Bionics 
  • Retinal implants from Second Sight
  • Insulin delivery from Medtronic
  • Cardiac rhythm management from St. Jude
  • Spinal cord stimulation from Boston Scientific
  • Functional rehabilitation from Bioness
  • Peripheral nerve stimulation (PNS) from Bioness

StimRouter Milestones

The StimRouter Neuromodulation System is an innovative technology that provides permanent relief for chronic pain. StimRouter therapy fills an important gap in the treatment algorithm between medications and more invasive procedures.
  • 2004
    Bioness develops technology that lays the foundation for the StimRouter PNS neuromodulation system.
  • 2014
    StimRouter received CE Mark approval to treat chronic pain of peripheral nerve origin
  • 2015
    StimRouter received FDA 510(k) approval to treat chronic pain of peripheral nerve origin
  • 2016
    Results from the Chronic Pain Randomized Control Trial published in
  • 2016
    StimRouter launched in the US and European markets as the only PNS device specifically designed to treat chronic peripheral nerve pain. Initiated an IDE clinical study for the use of StimRouter PNS as a treatment for overactive bladder and fecal incontinence.
  • 2018
    StimRouter receive Health Canada Approval for the treatment of chronic peripheral nerve pain
  • 2019
    Received CE Mark for the treatment of overactive bladder. StimRouter received additional FDA 510(k) approval for product innovations. StimRouter data highlighted in five clinical publications including a prospective case series in Pain Management.
  • 2020
    StimRouter receives CE Mark for faecal incontinence.